|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | The wonders of BMP9:From mesenchymal stem cell differentiation,angiogenesis,neurogenesis,tumorigenesis,and metabolism to regenerative medicine显示文摘Although bone morphogenetic proteins(BMPs)initially showed effective induction of ectopic bone growth in muscle,it has since been determined that these proteins,as members of the TGF-b superfamily,play a diverse and critical array of biological roles.These roles include regulating skeletal and bone formation,angiogenesis,and development and homeostasis of multiple organ systems.Disruptions of the members of the TGF-b/BMP superfamily result in severe skeletal and extra-skeletal irregularities,suggesting high therapeutic potential from understanding this family of BMP proteins.Although it was once one of the least characterized BMPs,BMP9 has revealed itself to have the highest osteogenic potential across numerous experiments both in vitro and in vivo,with recent studies suggesting that the exceptional potency of BMP9 may result from unique signaling pathways that differentiate it from other BMPs.The effectiveness of BMP9 in inducing bone formation was recently revealed in promising experiments that demonstrated efficacy in the repair of critical sized cranial defects as well as compatibility with bone-inducing bio-implants,revealing the great translational promise of BMP9.Furthermore,emerging evidence indicates that,besides its osteogenic activity,BMP9 exerts a broad range of biological functions,including stem cell differentiation,angiogenesis,neurogenesis,tumorigenesis,and metabolism.This review aims to summarize our current understanding of BMP9 across biology and the body. | Sami Mostafa Mikhail Pakvasa Elam Coalson Allen Zhu Alex Alverdy Hector Castillo Jiaming Fan Alex Li Yixiao Feng Di Wu Elliott Bishop Scott Du Mia Spezia Alissa Li Ofir Hagag Alison Deng Winny Liu Mingyang Li Sherwin S·Ho Aravind Athiviraham Michael J·Lee Jennifer Moriatis Wolf Guillermo A·Ameer Hue H·Luu Rex C·Haydon Jason Strelzow Kelly Hynes Tong-Chuan He Russell R·Reid | 2019 | Genes & Diseases2019，6，3： | 15 |
| 2 | Solving nonstationary classification problems with coupled support vector machines显示文摘 | Guillermo L G Lucas C U Alejandro C H | 2011 | IEEE Trans on Knowledge on Neural Network2011，22，1： | 1 |
| 3 | Hydrogenation of edible oil, over Pd catalysts: A combined theoretical and experimental study显示文摘 | Maria B F Gabriela M T Guillermo H C | 2005 | Journal of Molecular Catalysis A : Chemical2005，237，2： | 1 |
| 4 | Pseudopemphigoid as caused by topical drugs and pemphigus disease显示文摘Pseudopemphigoid can cause a chronic cicatricial conjunctivitis that is clinically identical to the manifestations seen in mucous membrane pemphigoid, a disorder with a common clinical phenotype and multiple autoimmune links. For the purpose of this review, we will describe pseudopemphigoid as caused by topical drugs, the most common etiology with ocular manifestations, and as caused by the pemphigus disease, a more rare etiology. Specifically, we will discuss the ophthalmological features of drug-induced cicatricial conjunctivitis, pemphigus vulgaris, and paraneoplastic pemphigus. Other etiologies of pseudopemphigoid exist that will not be described in this review including autoimmune or inflammatory conditions such as lichen planus, sarcoidosis, granulomatosis with polyangiitis(Wegener's granulomatosis), erythema multiforme(minor, major, and Stevens-Johnson syndrome), bullous pemphigoid, skin-dominated linear IgA bullous dermatosis, and skin-dominated epidermolysis bullosa acquisita. Prompt diagnosis of the underlying etiology in pseudopemphigoid is paramount to the patient's outcome as certain diseases are associated with a more severe clinical course, increased ocular involvement, and differential response to treatment. A completehistory and ocular examination may find early cicatricial changes in the conjunctiva that are important to note and evaluate to avoid progression to more severe disease manifestations. When such cicatricial changes are noted, proper diagnostic techniques are needed to help elucidate a diagnosis. Lastly, collaboration between ophthalmologists and subspecialists such as dermatologists, pathologists, immunologists, and others involved in the care of the patient is needed to ensure optimal management of disease. | Laura C Huang James R Wong Javier Alonso-Llamazares Carlos H Nousari Victor L Perez Guillermo Amescua Carol L Karp Anat Galor | 2015 | World Journal of Ophthalmology2015，5，1： | 1 |
| 5 | Solving nonstationary classification problems with coupled support vector machines显示文摘 | Guillermo L G Lucas C U Alejandro C H | 2011 | IEEE Trans on Knowledge on Neural Network2011，22，1： | 1 |
| 6 | Enzymatic acidolysis of sunflower oil with a palmitic-stearic acid mixture显示文摘 | MARIA E C GUILLERMO H C | 2008 | Journal of Food Engineering2008，84，2： | 1 |
| 7 | An international survey of classification and treatment choices for group D retinoblastoma显示文摘AIM: To determine which IIRC scheme was used by retinoblastoma centers worldwide and the percentage of D eyes treated primarily with enucleation versus globe salvaging therapies as well as to correlate trends in treatment choice to IIRC version used and geographic region.METHODS: An anonymized electronic survey was offered to 115 physicians at 39 retinoblastoma centers worldwide asking about IIRC classification schemes and treatment patterns used between 2008 and 2012. Participants were asked to record which version of the IIRC was used for classification, how many group D eyes were diagnosed, and how many eyes were treated with enucleation versus globe salvaging therapies. Averages of eyes per treatment modality were calculated and stratified by both IIRC version and geographic region. Statistical significance was determined by Chi-square, ANOVA and Kruskal-Wallis tests using Prism.RESULTS: The survey was completed by 29% of physicians invited to participate. Totally 1807 D eyes were diagnosed. Regarding IIRC system, 27% of centers used the Children's Hospital of Los Angeles(CHLA) version, 33% used the Children's Oncology Group(COG) version, 23% used the Philadelphia version, and 17% were unsure. The rate for primary enucleation varied between 0 and 100% and the mean was 29%. By IIRC version, primary enucleation rates were: Philadelphia, 8%; COG, 34%; and CHLA, 37%. By geographic region, primary enucleation rates were: Latin America, 57%; Asia, 40%; Europe, 36%; Africa, 10%, US, 8%; and Middle East, 8%. However, systemic chemoreduction was used more often than enucleation in all regions except Latin America with a mean of 57% per center(P<0.0001). CONCLUSION: Worldwide there is no consensus on which IIRC version is used, systemic chemoreduction was the most frequently used initial treatment during the study period followed by enucleation and primary treatment modality, especially enucleation, varied greatly with regards to IIRC version used and geographic region. | Christina Scelfo Jasmine H Francis Vikas Khetan Thomas Jenkins Brian Marr David H Abramson Carol L Shields Jacob Pe’er Francis Munier Jesse Berry J.William Harbour Andrey Yarovoy Evandro Lucena Timothy G Murray Pooja Bhagia Evelyn Paysse Samuray Tuncer Guillermo L Chantada Annette C Moll Tatiana Ushakova David A Plager Islamov Ziyovuddin Carlos A Leal Miguel A Materin Xun-Da Ji Jose W Cursino Rodrigo Polania Hayyam Kiratli Charlotta All-Ericsson Rejin Kebudi Santosh G Honavar Vicktoria Vishnevskia-Dai Sidnel Epelman Anthony B Daniels Jeanie D Ling Fousseyni Traore Marco A Ramirez-Ortiz | 2017 | International Journal of Ophthalmology(English edition)2017，10，6： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员